Trials / Completed
CompletedNCT04531462
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
A Randomised, Double-blind, Placebo-controlled, Parallel Group, 52 Weeks Phase IV Trial to Evaluate Efficacy and Safety of Oral, Once Daily Empagliflozin in Elderly Japanese Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is to assess the efficacy of empagliflozin 10 mg after 52 weeks compared to placebo in elderly patients with Type 2 diabetes mellitus (T2DM) and to explore if empagliflozin has any impact on patient physical condition compared to placebo in elderly patients with T2DM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin | Empagliflozin |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2020-10-05
- Primary completion
- 2022-08-19
- Completion
- 2022-08-26
- First posted
- 2020-08-28
- Last updated
- 2024-05-02
- Results posted
- 2024-03-12
Locations
18 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04531462. Inclusion in this directory is not an endorsement.